|
Olmos-Jiménez R, Díaz-Carrasco MS, Galera-Miñarro A, Pascual-Gazquez JF, Espuny-Miró A. Evaluation of standardized triple intrathecal therapy toxicity in oncohematological pediatric patients. Int J Clin Pharm. 2017 Feb;39(1):126-132. doi: 10.1007/s11096-016-0408-0. Epub 2016 Dec 8. PubMed PMID: 27933487.
AÑO: 2017; IF: 2.305
|
27933487
|
Olmos-Jiménez R, Espuny-Miró A, Cárceles Rodríguez C, Díaz-Carrasco MS. Practical aspects of the use of intrathecal chemotherapy. Farm Hosp. 2017 Jan 1;41(n01):105-129. doi: 10.7399/fh.2017.41.1.10616. Review. PubMed PMID: 28045655.
AÑO: 2017
|
|
Olmos-Jiménez R, Díaz-Carrasco MS, Cabañas-Perianes V, Valderrey-Pulido M, Espuny-Miró A. Evaluation of standardized triple intrathecal therapy toxicity in oncohematological adult patients. Farm Hosp. 2017 Sep 1;41(5):611-617. doi: 10.7399/fh.10762. PubMed PMID: 28847250.
AÑO: 2017
|
|
Olmos-Jiménez R, Espuny-Miró A, Díaz-Carrasco MS, Fernández-Varón E, Valderrey-Pulido M, Cárceles-Rodríguez C. Stability of four standardized preparations of methotrexate, cytarabine, and hydrocortisone for intrathecal use. J Oncol Pharm Pract. 2016 Oct;22(5):659-65. doi: 10.1177/1078155215600905. Epub 2015 Aug 12. PubMed PMID: 26271105.
AÑO: 2016; IF: 1.416
|
|
Fernández de Palencia Espinosa MÁ, Díaz Carrasco MS, Alonso Romero JL, de la Rubia Nieto A, Espuny Miró A. Potential drug-drug interactions in oncological adult inpatients at a Spanish hospital: epidemiology and risk factors. Int J Clin Pharm. 2015 Dec;37(6):1021-7. doi: 10.1007/s11096-015-0195-z. Epub 2015 Sep 21. PubMed PMID: 26391788.
AÑO: 2015; IF: 2.305
|